vTv Therapeutics (VTVT) Total Liabilities (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Total Liabilities data on file, last reported at $8.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 61.72% year-over-year to $8.9 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (down 61.72% YoY), and the FY2025 full-year result was $25.5 million, up 6.25% from the prior year.
• Total Liabilities slipped to $8.9 million in Q1 2026, from $25.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $29.6 million in Q2 2022 to a low of $8.9 million in Q1 2026.
• A 5-year average of $25.2 million and a median of $27.4 million in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities jumped 233.11% in 2022 and tumbled 61.72% in 2026, its largest moves.
• Tracing VTVT's Total Liabilities over 5 years: stood at $27.4 million in 2022, then rose by 7.91% to $29.6 million in 2023, then declined by 18.95% to $24.0 million in 2024, then gained by 6.25% to $25.5 million in 2025, then sank by 65.23% to $8.9 million in 2026.
• Business Quant data shows VTVT's Total Liabilities at $8.9 million in Q1 2026, $25.5 million in Q4 2025, and $29.0 million in Q3 2025.